Court ruling clears way for Novartis’ low-cost biotech drug
WASHINGTON (AP) — A federal appeals court has ruled that Novartis can begin selling its lower-cost copy of an Amgen Inc. drug in September, rejecting a bid to further delay the launch of the knock-off biotech medication.